About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below.

"At Catalyst, everything begins with patients. Our presence at these scientific meetings reflects our ongoing commitment to advancing differentiated therapies that can meaningfully impact the lives of patients we serve, supported by the strength of our clinical research collaborations," said Rich Daly, President and CEO of Catalyst.

Conference: Child Neurology Society (CNS) Annual Meeting 
Poster #: 281
Title: Association Between Glucocorticoid Treatment Duration and Healthcare Resource Utilization in Duchenne Muscular Dystrophy: A Real-World Analysis
Date of Presentation: Thursday, October 9, 2025
Time: Posters are available in Poster Hall from 11:30 am to 7:00 pm ET
Presented by: Steven D Woods, PharmD

Poster #: 353
Title: Glucocorticoid Use and Delayed Respiratory Decline in Duchenne Muscular Dystrophy Patients: A Real-World Analysis
Date of Presentation: Thursday, October 9, 2025
Time: Posters are available in Poster Hall from 11:30 am to 7:00 pm ET
Presented by: Bridget McGowan, MD

Conference: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting
Session Name: Poster Session I and II
Poster Number: 314
Poster Session I: Thursday, October 30, 6:15-6:45 pm PT
Poster Session II: Friday, October 31, 9:30-10:00 am PT
Title: Association Between Glucocorticoid Treatment Duration and Observed Adverse Clinical Outcomes in Duchenne Muscular Dystrophy: A Real-World Analysis
Dates of Presentations: Thursday October 30 and Friday, October 31
Presented by: Bridget McGowan, MD / Steven D Woods, PharmD

Conference: Myasthenia Gravis Foundation of America, Inc. (MGFA) Scientific Session at AANEM Annual Meeting
Session Name: MGFA Scientific Poster Session
Poster Number: 3
Title: Patient characteristics and time to stable dose with amifampridine phosphate in the treatment Lambert Eaton Myasthenic Syndrome in the United States
Date of Presentation: Wednesday, October 29, 2025
Time: Poster presentation starts at 2:30 pm PT
Presented by: Yaacov Anziska, MD

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst's website at www.catalystpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.


Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
IR@catalystpharma.com

Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com

Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.19
+5.72 (2.64%)
AAPL  263.05
+0.81 (0.31%)
AMD  238.24
-2.32 (-0.96%)
BAC  51.48
-0.55 (-1.07%)
GOOG  251.55
-5.47 (-2.13%)
META  734.12
+1.95 (0.27%)
MSFT  518.23
+1.44 (0.28%)
NVDA  181.41
-1.23 (-0.68%)
ORCL  275.26
-1.92 (-0.69%)
TSLA  444.05
-3.38 (-0.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.